Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

8.6%

61 terminated/withdrawn out of 712 trials

Success Rate

90.7%

+4.2% vs industry average

Late-Stage Pipeline

35%

249 trials in Phase 3/4

Results Transparency

22%

131 of 592 completed trials have results

Key Signals

23 recruiting131 with results51 terminated10 withdrawn

Enrollment Performance

Analytics

Phase 1

182(28.6%)

Phase 2

181(28.4%)

Phase 3

155(24.3%)

Phase 4

94(14.8%)

N/A

22(3.5%)

Early Phase 1

3(0.5%)

637Total

Phase 1(182)

Phase 2(181)

Phase 3(155)

Phase 4(94)

+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (712)

Showing 20 of 712 trials

NCT02319837Phase 3Active Not Recruiting

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

Role: collaborator

NCT03182244Phase 3Active Not Recruiting

A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase 3 (FLT3) Mutation

Role: lead

NCT03971253Recruiting

Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

Role: lead

NCT03395197Phase 3Active Not Recruiting

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Role: collaborator

NCT07421700Phase 1Recruiting

Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer

Role: collaborator

NCT07484971Recruiting

Study of the Epidemiological, Clinical, Diagnostic, and Therapeutic Characteristics of Prostate Cancers in Algeria

Role: collaborator

NCT07318714Phase 1Recruiting

A Study of ASP2246 for People Who Have Movement Problems Caused by Brain Injury After a Stroke

Role: lead

NCT07094204Phase 1Recruiting

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Role: lead

NCT05382559Phase 1Recruiting

A Study of ASP3082 in Adults With Advanced Solid Tumors

Role: lead

NCT06206421Phase 3Completed

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

Role: lead

NCT06553885Phase 2Recruiting

Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC

Role: collaborator

NCT07483983Phase 2Recruiting

Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance

Role: collaborator

NCT07347314Phase 2Recruiting

Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy

Role: collaborator

NCT04821622Phase 3Active Not Recruiting

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Role: collaborator

NCT06130995Phase 1Recruiting

Relugolix + Enzalutamide Study in High-Risk Prostate Cancer

Role: collaborator

NCT06970665Phase 4Recruiting

A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration

Role: lead

NCT05968599Completed

A Study to Learn About the Study Medicines Called Enzalutamide and Abiraterone in People With Metastatic Castration-resistant Prostate Cancer

Role: collaborator

NCT07425808Phase 2Not Yet Recruiting

FLT3-ITD Targeted Therapy in Fit AML Patients

Role: collaborator

NCT06809140Phase 2Recruiting

Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer

Role: collaborator

NCT06470282Phase 1Recruiting

Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer

Role: collaborator